Immunity induced by Yellow Fever vaccination in the elderly (60 years or OLDer) traveller

2013 ◽  
Author(s):  
A.H.E. Roukens
Author(s):  
Juliana Araújo do Espírito Santo ◽  
Keli Bahia Felicíssimo Zocratto

Descrever a cobertura vacinal de febre amarela nos últimos cinco anos (2013 a 2017) nos municípios de Belo Horizonte, Nova Lima e Ribeirão das Neves.  Estudo descritivo onde foram utilizados dados secundários coletados em sites oficiais relativos ao período de 2013 a 2017 para os municípios de Belo Horizonte, Nova Lima e Ribeirão das Neves. No período analisado, foram aplicadas 1.687.937 doses da vacina contra febre amarela, sendo que a cobertura vacinal em Belo Horizonte caiu de 80% para 0,09% no ano de 2014. Observou-se maior concentração de doses aplicadas na faixa etária de 15 a 59 anos. Em idosos as doses aplicadas aumentaram de 1.888 para 68.570 no ano de 2017. Ressalta-se que a vacinação aumentou consideravelmente após o início da epidemia em 2016. Considerando os anos analisados, os três municípios mantiveram a cobertura vacinal próxima da meta determinada pelo Programa Nacional de Imunização.Descritores: Febre Amarela, Vacinação, Epidemia.Yellow fever: vaccine coverage in the metropolitan area of Belo HorizonteAbstract: To describe the vaccination coverage of yellow fever in the last five years (2013 to 2017) in the municipalities of Belo Horizonte, Nova Lima and Ribeirão das Neves. A descriptive study using secondary data collected from official sites for the period from 2013 to 2017 for the municipalities of Belo Horizonte, Nova Lima and Ribeirão das Neves. In the analyzed period, 1,687,937 doses of the yellow fever vaccine were applied, and vaccination coverage in Belo Horizonte fell from 80% to 0.09% in 2014. There was a higher concentration of doses applied in the range from 15 to 59 years. In the elderly, the doses increased from 1,888 to 68,570 in the year 2017. It should be emphasized that vaccination increased considerably after the onset of the epidemic in 2016. Considering the years analyzed, the three municipalities-maintained vaccination coverage close to the goal determined by the National Immunization Program.Descriptors: Yellow Fever, Vaccination, Epidemic.Fiebre Amarilla: cobertura vacunal en la región metropolitana de Belo HorizonteResumen: Describir la cobertura vacunal de fiebre amarilla en los últimos cinco años (2013 a 2017) en los municipios de Belo Horizonte, Nova Lima y Ribeirão das Neves. Estudio descriptivo donde se utilizaron datos secundarios recogidos en sitios oficiales relativos al período de 2013 a 2017 para los municipios de Belo Horizonte, Nova Lima y Ribeirão das Neves. En el período analizado, se aplicaron 1.687.937 dosis de la vacuna contra la fiebre amarilla, siendo que la cobertura vacunal en Belo Horizonte bajó del 80% al 0,09% en el año 2014. Se observó una mayor concentración de dosis aplicadas en el rango de 15 a 59 años. En los ancianos las dosis aplicadas aumentaron de 1.888 a 68.570 en el año 2017. Se resalta que la vacunación aumentó considerablemente después del inicio de la epidemia en 2016. Considerando los años analizados, los tres municipios mantuvieron la cobertura vacunal próxima a la meta determinada por el Programa Nacional de Inmunización.Descriptores: Fiebre Amarilla, Vacunación, Epidemia. 


Vaccine ◽  
2020 ◽  
Vol 38 (52) ◽  
pp. 8286-8291
Author(s):  
Nicole P. Lindsey ◽  
Lori Perry ◽  
Marc Fischer ◽  
Tabitha Woolpert ◽  
Brad J. Biggerstaff ◽  
...  

2021 ◽  
pp. 135245852110063
Author(s):  
Caroline Papeix ◽  
Julie Mazoyer ◽  
Elisabeth Maillart ◽  
Caroline Bensa ◽  
Anne-Laure Dubessy ◽  
...  

Background: Yellow fever vaccine (YFV) is not advised for multiple sclerosis (MS) patients because of the potential risk of post-vaccine relapses. Objective: To assess the risk of relapsing-remitting multiple sclerosis (RR-MS) worsening after YFV. Methods: Non-interventional observational retrospective, exposed/non-exposed cohort study nested in the French national cohort including MS. Results: 128 RR-MS were included. The 1-year annualized relapse rate (ARR) following YFV did not differ between exposed: 0.219 (0.420) and non-exposed subjects: 0.208 (0.521) ( p = 0.92). Time to first relapse was not different between groups (adjusted hazard ratio (HR) = 1.33; 95% confidence interval (CI) = 0.53–3.30, p = 0.54). Conclusion: These results suggest that YFV does not worsen the course of RR-MS.


Sign in / Sign up

Export Citation Format

Share Document